[MO43] Mini-Oral Session 43　消化器5（消化管がん）
【E】

[MO43-6] Safety and efficacy of anti-PD-1 antibody dostarlimab in patients with mismatch repair-deficient (dMMR) solid cancers

^○Thierry Andre¹, Dominique Berton², Giuseppe Curigliano³, Susan L Ellard⁴, Jose Manuel Trigo Perez⁵, Hendrik-Tobias Arkenau⁶, Cyril Abdeddaim⁷, Wei Guo⁸, Ellie Im⁹, Naureen Starling¹⁰ (1.Sorbonne University and Saint-Antoine Hospital, 2.GINECO & Institut de Cancerologie de l'Ouest, Centre René Gauducheau, 3.Division of Early Drug Development for Innovative Therapies, IEO, European Institute of Oncology IRCCS, and University of Milano, 4.BC Cancer-Kelowna, 5.Medical Oncology Department, Hospital Ramón y Cajal, 6.Sarah Cannon Research Institute UK Limited, 7.Centre de Lutte Contre le Cancer-Centre Oscar Lambret, 8.START Madrid-FJD, Fundación Jiménez Diaz Hospital, 9.GlaxoSmithKline (GSK), 10.Royal Marsden Hospital NHS Foundation Trust)